Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amicus Therapeutics

6.03
-0.1300-2.11%
Post-market: 6.120.0898+1.49%18:27 EDT
Volume:4.60M
Turnover:27.99M
Market Cap:1.86B
PE:-62.73
High:6.20
Open:6.19
Low:6.02
Close:6.16
Loading ...

Is Amicus Therapeutics Inc. (FOLD) the Best Nasdaq Stock Under $20 to Buy Now?

Insider Monkey
·
18 Mar

KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug

Zacks
·
03 Mar

US High Growth Tech Stocks With Strong Potential

Simply Wall St.
·
01 Mar

U.S. RESEARCH ROUNDUP-Autodesk, Coca-Cola, NetApp

Reuters
·
28 Feb

Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025

GlobeNewswire
·
27 Feb

Why Amicus Therapeutics, Inc. (FOLD) is the Most Oversold Pharma Stock to Buy According to Analysts

Insider Monkey
·
24 Feb

Amicus Therapeutics: Strategic Market Expansion and Robust Sales Drive Buy Rating

TIPRANKS
·
23 Feb

Amicus Therapeutics Navigates Potential Risks Amid U.S. Trade Policy Changes

TIPRANKS
·
21 Feb

Stock Track | Amicus Therapeutics Plummets 5% as Growth Outlook for PomOp Disappoints

Stock Track
·
20 Feb

Amicus Therapeutics Full Year 2024 Earnings: EPS Beats Expectations

Simply Wall St.
·
20 Feb

Amicus Therapeutics Inc (FOLD) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

GuruFocus.com
·
20 Feb

Q4 2024 Amicus Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents
·
20 Feb

Amicus Therapeutics Posts Robust 2024 Financial Growth

TIPRANKS
·
20 Feb

Amicus Therapeutics: Promising Growth and Strong Financial Guidance Justify Buy Rating

TIPRANKS
·
20 Feb

BRIEF-Amicus Therapeutics Inc Files For Mixed Shelf Size Not Disclosed - SEC Filing

Reuters
·
20 Feb

Amicus Therapeutics Inc Files for Mixed Shelf; Size Not Disclosed - SEC Filing

THOMSON REUTERS
·
20 Feb

Stock Track | Amicus Therapeutics Plummets 7.51% Pre-market as Q4 Earnings Miss Estimates

Stock Track
·
19 Feb

Amicus Therapeutics (FOLD) Q4 Earnings and Revenues Miss Estimates

Zacks
·
19 Feb

Amicus Therapeutics' Q4 Non-GAAP Earnings, Net Product Revenue Rise

MT Newswires Live
·
19 Feb

Amicus Therapeutics Inc Outlook FY Total Revenue Growth 17% to 24%

THOMSON REUTERS
·
19 Feb